A study funded by a Canadian biopharmaceutical company estimates that the combined health-care and productivity costs to Canada from verotoxigenic E. coli-related (VTEC) infections total about $404 million per year. The peer-reviewed study, to be published in the Journal of Food Protection, indicates that 93 percent of VTEC infections are caused by the E. coli…

Food safety cooperative VeriPrime has proposed a pilot program that would test the preventive effectiveness of E. coli vaccines in cattle and expand their use. “We’re looking to reduce E. coli in beef and E. coli in the environment as well,” said veterinarian Scott Crain, VeriPrime founder and CEO. The five-year on-farm intervention would begin…

The recent largest beef recall in Canadian history and its resulting economic and health consequences illustrates the complexities and difficulties associated with Canadian beef safety. However, there is currently a simple, unused, practical and economically viable solution to avoiding such beef recalls as well as preventing E. coli O157 outbreaks — we should vaccinate cattle…

A Canadian vaccine designed to reduce E. coli O157:H7 shedding in cattle has become the first drug of its kind to be approved for use in the United Kingdom. The medication – manufactured by Bioniche Life Sciences, Inc. – was granted a Special Treatment Certificate (STC) by the UK’s Veterinary Medical Directorate, a branch of…

Vaccines administered by Cargill Meat Solutions to 85,000 head of cattle in the Fort Morgan, CO area this past May through August are showing potential promise for reducing E. coli O157:H7 in beef.

Cargill’s large-scale tests of E coli O157:H7 vaccines, announced last January, were successful enough that the meat giant rolled out some of …

A dozen or so feedlots around the Fort Morgan, CO beef plant owned by Cargill Meat Solutions have been enlisted in a field trial for a vaccine against E. coli O157:H7.

The plan, according to Cargill’s Mark Klein, is to give the vaccine to about 100,000 cattle that will be slaughtered at the Fort Morgan …

Whether new vaccines against E. coli O157:H7 can work well enough to be economically viable could be decided by new large field trials that are just getting underway.

Two vaccines are in trial.  Willmar, MN-based Epitopix gained approval about ten months ago for sales of its vaccine against E. coli in the United States.  Claiming …